BackgroundRuthenium (Ru) tetraamines are being increasingly used as nitric oxide (NO)
carriers. In this context, pharmacological studies have become highly relevant to
better understand the mechanism of action involved.ObjectiveTo evaluate the vascular response of the tetraamines
trans-[RuII(NH3)4(Py)(NO)]3+,
trans-[RuII(Cl)(NO) (cyclan)](PF6)2, and
trans-[RuII(NH3)4(4-acPy)(NO)]3+.MethodsAortic rings were contracted with noradrenaline (10−6 M). After voltage
stabilization, a single concentration (10−6 M) of the compounds was
added to the assay medium. The responses were recorded during 120 min. Vascular
integrity was assessed functionally using acetylcholine at 10−6 M and
sodium nitroprusside at 10−6 M as well as by histological
examination.ResultsHistological analysis confirmed the presence or absence of endothelial cells in
those tissues. All tetraamine complexes altered the contractile response induced
by norepinephrine, resulting in increased tone followed by relaxation. In rings
with endothelium, the inhibition of endothelial NO caused a reduction of the
contractile effect caused by pyridine NO. No significant responses were observed
in rings with endothelium after treatment with cyclan NO. In contrast, in rings
without endothelium, the inhibition of guanylate cyclase significantly reduced the
contractile response caused by the pyridine NO and cyclan NO complexes, and both
complexes caused a relaxing effect.ConclusionThe results indicate that the vascular effect of the evaluated complexes involved
a decrease in the vascular tone induced by norepinephrine (10−6 M) at
the end of the incubation period in aortic rings with and without endothelium,
indicating the slow release of NO from these complexes and suggesting that the
ligands promoted chemical stability to the molecule. Moreover, we demonstrated
that the association of Ru with NO is more stable when the ligands pyridine and
cyclan are used in the formulation of the compound.